Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Phosphatidylinositol (3,4,5)-trisphosphate) (PIP3) is crucial for cell functions.
• Dysregulated PIP3 signaling drives cancer progression.
• PTEN (phosphatase and tensin homolog) counteracts PIP3 signaling and acts as a tumor suppressor.

Purpose of the Study:

• To engineer an enhanced PTEN (ePTEN) with increased activity against PIP3 signaling.
• To investigate ePTEN as a potential cancer therapeutic strategy.

Main Methods:

• Utilized a heterologous expression system with human PTEN-GFP in Dictyostelium cells.
• Identified and engineered mutations in PTEN's membrane-binding interface.
• Assessed ePTEN's ability to suppress PIP3 levels, AKT phosphorylation, and cell proliferation/migration in human cells.

Main Results:

• Discovered mutations enhancing PTEN recruitment to the plasma membrane via PI(4,5)P2.
• Developed ePTEN with an eightfold increase in PIP3 signaling suppression.
• Demonstrated that ePTEN reduces PIP3, AKT phosphorylation, and cell proliferation/migration in human cells.

Conclusions:

• PTEN activation can effectively re-regulate PIP3 signaling.
• Engineered PTEN (ePTEN) shows promise as a feasible target for anticancer therapies.